New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
09:25 EDTVRTX, VRTXVertex management to meet with JMP Securities
Meeting to be held in Chicago on March 19 hosted by JMP Securities.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
15:22 EDTVRTXVertex CEO says 'way too early' to talk about pricing for new CF combo drug
Vertex CEO Jeff Leiden speaking on CNBC.
07:36 EDTVRTXVertex price target raised to $146 from $125 at Piper Jaffray
Piper Jaffray raised its price target for Vertex Pharmaceuticals shares to $146 citing continued Kalydeco growth after the company issued 2015 guidance. Piper reiterates an Overweight rating on Vertex.
January 11, 2015
21:04 EDTVRTXVertex expects Q4 Kalydeco revenue $460M
Subscribe for More Information
21:03 EDTVRTXVertex sees 2015 Kalydeco revenue $560M-$580M
Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. It said the increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor. Vertex's expected non-GAAP R&D and SG&A expenses exclude stock-based compensation expense and certain other expenses recorded in 2015. Vertex said entered 2015 with approximately $1.4B in cash, cash equivalents and marketable securities. Anticipated 2015 Kalydeco net revenues reflect: Use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; Use of KALYDECO in people in the United States with the R117H mutation following FDA approval in late 2014; The completion of reimbursement discussions for gating mutations in certain European countries; Use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015.
21:00 EDTVRTXVertex says NDA for combination of lumacaftor, ivacaftor accepted by FDA
Subscribe for More Information
20:57 EDTVRTXVertex says NDA for ivacaftor use in children accepted by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use